Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International    BAX

News SummaryMost relevantAll newsSector newsTweets 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
06/27 BAXTER INTERNATIONAL : Announces DoseEdge Bi-Directional Integration With Epic i..
06/26 BAXTER INTERNATIONAL : Announces DoseEdge Bi-Directional Integration with Epic i..
06/22 United States Anesthesia Drugs Market & Forecast
06/15 BAXTER INTERNATIONAL : Presents Data on Telehealth's Role in Improving Peritonea..
06/15 BAXTER INTERNATIONAL : Announces U.S. FDA Approval and Commercial Launch of Read..
06/15 BAXTER INTERNATIONAL : New Data Demonstrates High Performance of HDx Enabled by ..
06/15 BAXTER INTERNATIONAL : Announces Agreement with Dorizoe Lifesciences to Further ..
06/14 BAXTER INTERNATIONAL : Announces Agreement with Dorizoe Lifesciences to Further ..
06/13 BAXTER INTERNATIONAL : The #1 Bet of the World's Leading Activist Investor
06/09 BAXTER INTERNATIONAL : and Mayo Clinic Launch Research and Development Collabora..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/05 Pearson rally, miners help FTSE surge to strongest week since March
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
06/27 BAXTER : Solid Upward Ride In The Future
06/14 Baxter teams up with Dorizoe to develop generic injectables
06/09 What's Driving The Euro Higher And 4 Stocks That Will Benefit
06/07 Chanos bearish on dialysis companies on unsustainability of Obamacare-covered..
06/07 Should You Bet Along With Hedge Fund Managers On Baxter International?
Financials ($)
Sales 2017 10 367 M
EBIT 2017 1 627 M
Net income 2017 1 133 M
Finance 2017 53,7 M
Yield 2017 0,92%
P/E ratio 2017 31,60
P/E ratio 2018 26,07
EV / Sales 2017 3,19x
EV / Sales 2018 3,00x
Capitalization 33 153 M
More Financials
Duration : Period :
Baxter International Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIONAL
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 60,5 $
Spread / Average Target -0,85%
Consensus details
EPS Revisions
More Estimates Revisions
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC25.23%122 105
C R BARD INC40.71%22 882
TERUMO CORP4.51%15 488
More Results